In short
Clinical trials are investigating AZD6234 as part of studies for weight loss in people with obesity or overweight. These trials look at safety, tolerability, and how well AZD6234 works alone or with AZD9550. The studies include adults with obesity or overweight, with or without type 2 diabetes.
Key points
- AZD6234 is being studied in clinical trials for weight loss in people with obesity or overweight. One authorised Phase 2 study is testing AZD6234 with AZD9550 against placebo, mainly measuring body weight change after 36 weeks and the number of people who lose at least 5% of body weight. Another authorised early-phase study is looking at AZD6234 with AZD9550 in people with overweight or obesity, with or without type 2 diabetes. That study focuses on safety, tolerability, pharmacokinetics, and pharmacodynamics. Together, the trials show that AZD6234 is being researched as part of treatment strategies for weight management.
Trial overview
Two authorised clinical trials are investigating AZD6234 in people with obesity or overweight. One study is a Phase 2 weight loss trial, and the other is an early-phase study that includes Phase 1 and Phase I/II parts.
The studies are focused on weight management and on checking how safe and tolerable the study treatments are. One trial studies AZD6234 together with AZD9550, while the other looks at AZD6234 as part of a co-administration study with AZD9550.
Who can join the studies
The Phase 2 study includes people with obesity or overweight condition correlated to many co-morbidities. A co-morbidity is another health problem that happens along with the main condition.
The Phase 1 / Phase I/II study includes participants living with obesity and overweight, with or without type 2 diabetes mellitus. This means the study is not limited to people with diabetes, but it can include them.
What is being measured
In the Phase 2 study, the main outcomes are percent change in body weight from baseline after 36 weeks of treatment and the proportion of participants who lose at least 5% of body weight after 36 weeks. Baseline means the starting point before treatment begins.
The early-phase study mainly measures safety and tolerability through adverse events, serious adverse events, vital signs, ECG, and clinical laboratory tests. It also measures pharmacokinetics in part of the study, which describes how the body handles the treatment over time.
Trial phases and study design
The Phase 2 study is an interventional trial, which means the researchers give study treatments and then measure the results. It has an enrollment of 360 participants and is currently authorised.
The other study is also interventional and is described as a Phase I/II, randomised, single-blind, placebo-controlled, multiple-ascending-dose study. Randomised means participants are assigned by chance, single-blind means not everyone knows which treatment is given, placebo-controlled means a dummy treatment is used for comparison, and multiple-ascending-dose means the dose is increased in steps across groups.
This early study has an enrollment of 176 participants and is also authorised. Its design is meant to build early evidence on safety before larger studies move forward.
Study treatments and comparison groups
In the Phase 2 study, AZD6234 is tested in combination with AZD9550 against placebo, and the study also compares each drug alone in the trial design described in the title. This helps researchers see whether the combination works better than no active treatment.
In the early-phase study, participants receive AZD9550 alone or AZD9550 together with AZD6234, with matching placebo groups for comparison. The trial also includes different parts that test repeat dosing and multiple dose increases.
The trial records list several supporting medicines and test materials, but the main study focus for this article is the AZD6234 research program and its comparison groups.
What the trial data show so far
Both studies are currently listed as Authorised, which means they have approval to run based on the trial data provided. The available information shows that AZD6234 is being studied for weight loss in adults with obesity or overweight, including some people with type 2 diabetes.
At this stage, the key question is whether AZD6234, especially when used with AZD9550, can help reduce body weight while remaining safe and tolerable in the study groups.